|
|
|
| The treatment of GI malignancies has changed remarkably throughout the past several years with the advent of targeted agents. This activity will address three subsets of GI malignancies: CRC, gastric cancer (GC), and hepatocellular cancer (HCC). The activity will begin with an overview of each disease entity, diagnostic work-up, risk factors, prognostic indicators, current and evolving treatment options, and treatment-related toxicities. Nurse-centric case studies will be incorporated throughout the curriculum to provide participants with the opportunity to exercise knowledge transfer from the didactic presentations into constructive and relevant nursing practice. |
|
|
| |
|
|
|
| The incidence of melanoma has been growing rapidly in the United States, but no new agents have been approved to treat the disease in more than 10 years. There are four types of standard treatment used: surgery, chemotherapy, radiation therapy, and biologic therapy. The activity will begin with an overview of melanoma and the unique mechanism of action of immunomodulatory antibodies, presented in 3-D video animation. This will be followed by an overview of the 2009 American Joint Committee on Cancer recent staging updates, risk factors, novel molecular profiling techniques, and the current treatment regimens for different stages of melanoma. |
|
|
| |
|
|
|
| Treatment of CML is among the most rapidly evolving fields in hematology. This is primarily attributed to progress in our understanding of the biology of CML and treatment responses. As a result of recent data from ongoing trials, consensus-based treatment will likely evolve and changes in guidelines are expected. This symposium will address four major topics: updated treatment strate- gies, monitoring responses, evidence-based symptom management, and patient education resources. A video case study will be presented, illustrating a complicated outpatient CML scenario, beginning with the diagnostic work-up through the treatment trajectory. |
|
|
| |
|
|
|
| Bone health is emerging as an important issue among clinicians who care for patients with cancer. The incidence of bone metastases is 73% in patients with metastatic breast cancer, 68% in those with prostate cancer, and in nearly all patients with myeloma. The activity will begin with an overview of the symptoms, diagnosis, and assessment of bone disease in patients with cancer. This will be followed by a discussion of the National Comprehensive Cancer Network (NCCN) Task Force’s recent findings on progress made in screening techniques, therapeutic options for management, factors resulting in bone loss and bone metastases, and strategies to minimize bone recurrences. |
|
|
| |
|
|
|
| Lung cancer is the most common cause of cancer mortality in the United States. The focus on treating lung cancer is evolving towards personalized medicine, particularly now that advances in molecular biology and pharmacogenomics have led to improved detection and individualized treatment. This activity will review molecular characterization of NSCLC and its role in guiding treatment decisions and optimal patient management strategies. |
|
|
| |
|
|
|
|
In this educational activity, 150 nurses will be divided into groups of nine nurses per roundtable led by one NHL nurse thought leader faculty. Nurses will be encouraged to sit at a table that corresponds with their primary work setting. The symposium will be broken out by follicular lymphoma and mantle cell lymphoma. A hematology physician thought leader will provide an overview of staging/diagnosis and treatment for newly diagnosed, relapsed, and salvage settings |
|
|
| |